Cytokinetics heart failure drug succeeds but slightly higher death rate seen - study

By Deena Beasley (Reuters) - Cytokinetics Inc on Friday said a pivotal trial of the experimental heart failure drug it is developing with Amgen Inc showed a slightly higher rate of cardiovascular-related death for patients given the medicine compared to those on a placebo. Details presented at annual meeting of the American Heart Association (AHA) held virtually this year follow the release in October of initial results for the 8,256-patient trial

Reuters November 14, 2020 00:12:26 IST
Cytokinetics heart failure drug succeeds but slightly higher death rate seen - study

Cytokinetics heart failure drug succeeds but slightly higher death rate seen  study

By Deena Beasley

(Reuters) - Cytokinetics Inc on Friday said a pivotal trial of the experimental heart failure drug it is developing with Amgen Inc showed a slightly higher rate of cardiovascular-related death for patients given the medicine compared to those on a placebo.

Details presented at annual meeting of the American Heart Association (AHA) held virtually this year follow the release in October of initial results for the 8,256-patient trial. That announcement said the drug, omecamtiv mecarbil, met its main trial combination goal of reducing the risk of heart related death or need for hospitalization and other urgent care.

The benefit, while deemed statistically significant, was not dramatic, with those events occurring in 37% of trial patients treated with the medicine versus 39.1% of the placebo group.

Researchers said on Friday that 809, or 19.6%, of trial patients treated with omecamtiv mecarbil died, compared with 798, or 19.4%, of patients assigned to a placebo.

Patients in the study were considered to be at risk of hospitalization and death, despite being well treated with standard therapy.

The drug is designed to work by activating cardiac myosin, a protein in heart muscle cells responsible for converting chemical energy into the mechanical force that drives cardiac contraction.

Cytokinetics said the Phase III trial did not meet any of its other secondary goals, although a "potentially greater treatment effect" was suggested in patients with a lower left ventricular ejection fraction.

Heart failure, a chronic condition in which the heart becomes unable to pump blood efficiently, affects more than 64 million people worldwide. It is the leading cause of hospitalization and hospital readmission in people age 65 and older.

(Reporting By Deena Beasley; Editing by Bill Berkrot)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Facebook releases first data on hate speech prevalence on its platform
News & Analysis

Facebook releases first data on hate speech prevalence on its platform

By Elizabeth Culliford (Reuters) - Facebook Inc for the first time on Thursday disclosed numbers on the prevalence of hate speech on its platform, saying that out of every 10,000 content views in the third quarter, 10 to 11 included hate speech. The world's largest social media company, under scrutiny over its policing of abuses, particularly around November's U.S.

Santa, barred from malls and chimneys, enters homes via interactive video
News & Analysis

Santa, barred from malls and chimneys, enters homes via interactive video

(Reuters) - Santa cannot sit with kids in shopping malls this year, but they can still tell him their Christmas wishlist in a video chat at home.     Technology company Storyfile has come up with an artificial intelligence alternative to the holiday tradition: an interactive website where Father Christmas answers questions as if in person

Facebook estimates hate speech seen in 1 out of 1000 views on its platform
News & Analysis

Facebook estimates hate speech seen in 1 out of 1000 views on its platform

By Elizabeth Culliford (Reuters) - Facebook Inc for the first time on Thursday disclosed numbers on the prevalence of hate speech on its platform, saying that out of every 10,000 content views in the third quarter, 10 to 11 included hate speech. The world's largest social media company, under scrutiny over its policing of abuses, particularly around November's U.S.